drugset
drugset / Trial / NCT00532909

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

NCT00532909 ↗

Phase 1 Completed 13 enrolled Branimir Sikic AstraZeneca · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the maximum tolerated dose of Vandetanib with a current standard first-line chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the first line treatment of metastatic colorectal cancer (CRC) and to define the dose limiting toxicities associated with the combination.

Timeline

Start
2006-07
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Subject Capecitabine Small molecule 800 mg/m2 Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Oxaliplatin Small molecule 100 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Vandetanib Small molecule 100 mg Oral
Subject Vandetanib Small molecule 300 mg Oral

Indications

colorectal cancer